Woodline Partners LP - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.

Quarter-by-quarter ownership
Woodline Partners LP ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q4 2021$2,899,000
+24.4%
132,117
+52.9%
0.04%
+10.5%
Q3 2021$2,331,000
+150.1%
86,423
+123.3%
0.04%
+123.5%
Q2 2021$932,000
-75.0%
38,708
-54.9%
0.02%
-79.5%
Q1 2021$3,723,000
-13.2%
85,829
-17.0%
0.08%
-27.2%
Q4 2020$4,288,000103,4530.11%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 945,382$22,765,0005.92%
Octagon Capital Advisors LP 831,267$20,017,0004.15%
BVF INC/IL 2,005,862$48,301,0001.81%
Casdin Capital, LLC 1,115,555$26,863,0000.68%
Eagle Health Investments LP 57,090$1,375,0000.47%
Soleus Capital Management, L.P. 100,800$2,427,0000.37%
VIKING GLOBAL INVESTORS LP 3,937,914$94,825,0000.29%
ArrowMark Colorado Holdings LLC 1,029,897$24,800,0000.19%
Perceptive Advisors 750,512$18,072,0000.12%
Virtus ETF Advisers LLC 7,642$184,0000.08%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders